BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31996469)

  • 1. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer.
    Oliveira KCS; Ramos IB; Silva JMC; Barra WF; Riggins GJ; Palande V; Pinho CT; Frenkel-Morgenstern M; Santos SEB; Assumpcao PP; Burbano RR; Calcagno DQ
    Mol Cancer Res; 2020 Apr; 18(4):517-528. PubMed ID: 31996469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA.
    Ritch E; Wyatt AW
    Urol Oncol; 2018 Aug; 36(8):380-384. PubMed ID: 29248429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
    Moldogazieva NT; Zavadskiy SP; Terentiev AA
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.
    Filipska M; Rosell R
    Mol Oncol; 2021 Jun; 15(6):1667-1682. PubMed ID: 33969622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory implications of ctDNA in immuno-oncology for solid tumors.
    Vellanki PJ; Ghosh S; Pathak A; Fusco MJ; Bloomquist EW; Tang S; Singh H; Philip R; Pazdur R; Beaver JA
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology.
    Muinelo-Romay L; Casas-Arozamena C; Abal M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.
    Sanz-Garcia E; Zhao E; Bratman SV; Siu LL
    Sci Adv; 2022 Jan; 8(4):eabi8618. PubMed ID: 35080978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.
    Morris VK; Strickler JH
    Annu Rev Med; 2021 Jan; 72():399-413. PubMed ID: 33502901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.